title: [Cell therapy for ischemic heart disease].
abstract: Ischemic heart disease is the leading cause of death and heart failure worldwide. That is why it is important to develop new therapeutic modalities to decrease mortality and long-term complications in these patients. One of the main lines of research worldwide is myocardial regeneration, using progenitor cells in order to improve systolic and diastolic function in patients with ischemic heart disease, as well as to increase their survival. There have been carried out, with great enthusiasm worldwide, human and animal studies to define the usefulness of stem cells in the management of patients with ischemic heart disease. Today, regenerative therapy in ischemic heart disease is considered a novel therapeutic tool, with substantial theoretical benefits and few side effects. Here we present the scientific principles that support the use of this therapy, discuss the current clinical evidence available; and point out the controversial issues still not clarified on its use and usefulness in the short and long term.
authors.affiliation: Instituto Nacional de Cardiología Ignacio Chávez, México D.F., México. cardieu@hotmail.com
authors.forename: Carlos David
authors.initials: CD
authors.lastname: Escobedo-Uribe
authors.forename: Adriana Elizabeth
authors.initials: AE
authors.lastname: Monsiváis-Urenda
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: López-Quijano
authors.forename: Jorge
authors.initials: J
authors.lastname: Carrillo-Calvillo
authors.forename: José Luis
authors.initials: JL
authors.lastname: Leiva-Pons
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Peña-Duque
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D017202:Myocardial Ischemia / Q000601:surgery*; D033581:Stem Cell Transplantation